Home / Publication / Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Publication

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Author(s): Alice Ke, Zoe Barter, Karen Rowland-Yeo, Lisa Almond

Year: July 20, 2016

Recommended for you

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Blog

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

On-Demand Webinar

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

Webinar

Essentials of Model-informed Drug Development in Oncology

Blog

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

Essentials of Model-informed Drug Development in Oncology

Newsletter sign up

Quick links

Solutions

Contact